PROGENICS PHARMACEUTICALS INC 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Mar 4, 2015
Insider Transaction Report
Form 4
ISRAEL ROBERT J
Sr. VP, Medical Affairs
Transactions
- Exercise/Conversion
Common Stock
2015-03-03$4.70/sh+5,000$23,500→ 40,050 total - Sale
Common Stock
2015-03-03$6.49/sh−5,000$32,450→ 35,050 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2015-03-03$6.49/sh−5,000$32,450→ 61,000 totalExercise: $4.70Exp: 2024-03-03→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]The Reporting Person is exercising options under this grant in pre-established increments under and in accordance with provisions of a previously established Plan of Sale under Rule 10b5-1, which was established in accordance with the policies and procedures of the Issuer.
- [F2]This transaction was executed in multiple trades at various price ranges. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The stock options become exercisable in three equal annual installments, commencing one year from the grant date.